Biology of Blood and Marrow Transplantation
Volume 12, Issue 8 , Pages 876-884 , August 2006

The Effect of KIR Ligand Incompatibility on the Outcome of Unrelated Donor Transplantation: A Report from the Center for International Blood and Marrow Transplant Research, the European Blood and Marrow Transplant Registry, and the Dutch Registry

  • Sherif S. Farag

      Affiliations

    • The Ohio State University, Columbus, Ohio
    • Corresponding Author InformationCorrespondence and reprint requests: Dr. Sherif S. Farag, Department of Internal Medicine, Division of Hematology and Oncology and The Comprehensive Cancer Center, The Ohio State University, A433A Starling-Loving Hall, 320 West Tenth Avenue, Columbus, OH 43210
    • ,
  • Andrea Bacigalupo

      Affiliations

    • Ospedale S. Martino, Genova, Italy
    • ,
  • Mary Eapen

      Affiliations

    • Statistical Center, Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, Wisconsin
    • ,
  • Carolyn Hurley

      Affiliations

    • Georgetown University School of Medicine, Washington, DC
    • ,
  • Bo Dupont

      Affiliations

    • Memorial Sloan-Kettering Cancer Center, New York, New York
    • ,
  • Michael A. Caligiuri

      Affiliations

    • The Ohio State University, Columbus, Ohio
    • ,
  • Christian Boudreau

      Affiliations

    • University of Waterloo, Waterloo, Ontario, Canada
    • ,
  • Gene Nelson

      Affiliations

    • National Marrow Donor Program, Minneapolis, Minnesota
    • ,
  • Machteld Oudshoorn

      Affiliations

    • Leiden University Medical Center, Europdonor Foundation, Leiden, The Netherlands
    • ,
  • Jon van Rood

      Affiliations

    • Leiden University Medical Center, Europdonor Foundation, Leiden, The Netherlands
    • ,
  • Andrea Velardi

      Affiliations

    • Policlinico di Monteluce, Perugia, Italy
    • ,
  • Martin Maiers

      Affiliations

    • National Marrow Donor Program, Minneapolis, Minnesota
    • ,
  • Michelle Setterholm

      Affiliations

    • National Marrow Donor Program, Minneapolis, Minnesota
    • ,
  • Dennis Confer

      Affiliations

    • National Marrow Donor Program, Minneapolis, Minnesota
    • ,
  • Phillip E. Posch

      Affiliations

    • Georgetown University School of Medicine, Washington, DC
    • ,
  • Claudio Anasetti

      Affiliations

    • H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida
    • ,
  • Naynesh Kamani

      Affiliations

    • Children’s National Medical Center, Washington, DC
    • ,
  • Jeffrey S. Miller

      Affiliations

    • University of Minnesota, Minneapolis, Minnesota
    • ,
  • Daniel Weisdorf

      Affiliations

    • University of Minnesota, Minneapolis, Minnesota
    • ,
  • Stella M. Davies

      Affiliations

    • Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio
    • ,
  • KIR Study Group, Center for International Blood and Marrow Transplantation Research

Received 23 February 2006 ,Accepted 17 May 2006.

  • Image Result

    Cumulative incidence of TRM by donor–recipient HLA and KIR ligand matching. The 5-year rates were 45% after HLA-matched and KIR ligand–matched transplantations (n = 967), 62% after GVH KIR ligand–mism

    Cumulative incidence of TRM by donor–recipient HLA and KIR ligand matching. The 5-year rates were 45% after HLA-matched and KIR ligand–matched transplantations (n = 967), 62% after GVH KIR ligand–mismatched transplantations (n = 133), 54% after HLA-B and/or –C–mismatched but KIR-matched transplantations (n = 251), and 65% after HVG KIR ligand–mismatched transplantations (n = 161) (P < .001).

  • Image Result
    Cumulative incidence rates of relapse by donor–recipient HLA and KIR ligand matching. The 5-year rates were 16% after HLA-matched and KIR ligand–matched transplantations (n = 967), 18% after GVH KIR l

    Cumulative incidence rates of relapse by donor–recipient HLA and KIR ligand matching. The 5-year rates were 16% after HLA-matched and KIR ligand–matched transplantations (n = 967), 18% after GVH KIR ligand–mismatched transplantations (n = 133), 17% after HLA-B and/or –C–mismatched but KIR-matched transplantations (n = 251), and 10% after HVG KIR ligand–mismatched transplantations (n = 161) (P = not significant).

  • Image Result
    Probability of LFS by donor–recipient HLA and KIR ligand matching. The 5-year rates were 39% after HLA-matched and KIR ligand–matched transplantations (n = 967), 20% after GVH KIR ligand–mismatched tr

    Probability of LFS by donor–recipient HLA and KIR ligand matching. The 5-year rates were 39% after HLA-matched and KIR ligand–matched transplantations (n = 967), 20% after GVH KIR ligand–mismatched transplantations (n = 133), 29% after HLA-B and/or –C–mismatched but KIR-matched transplantations (n = 251), and 26% after HVG KIR ligand–mismatched transplantations (n = 161) (P < .001).

  • Image Result
    Probability of OS by donor–recipient HLA and KIR ligand matching. The 5-year rates were 42% after HLA-matched and KIR ligand–matched transplantations (n = 967), 24% after GVH KIR ligand–mismatched tra

    Probability of OS by donor–recipient HLA and KIR ligand matching. The 5-year rates were 42% after HLA-matched and KIR ligand–matched transplantations (n = 967), 24% after GVH KIR ligand–mismatched transplantations (n = 133), 31% after HLA-B and/or –C–mismatched but KIR-matched transplantations (n = 251), and 30% after HVG KIR ligand–mismatched transplantations (n = 161) (P < .001).

PII: S1083-8791(06)00374-0

doi: 10.1016/j.bbmt.2006.05.007

Biology of Blood and Marrow Transplantation
Volume 12, Issue 8 , Pages 876-884 , August 2006

Article Tools

* Image Usage & Resolution